Progressing Our Science

Biosimilars vs. Generics: What's the Difference?

Ushering in a New Era of Pfizer R&D Productivity

Building Upon a Heritage of Innovation in Biosimilars

Advancing Our Leading JAK Science

Furthering Pfizer's Global Anti-Infectives Leadership

Novel Anti-Infective Therapies Help Address Greatest Patient Medical Needs

Using Breakthrough Science to Transform the Treatment of Cancer

Sharing data from our clinical trials with trial participants and members of the research community to advance scientific progress

Leading the Way With Gene Therapy in Rare Disease

Progressing the Science in Duchenne Muscular Dystrophy

Overcoming Therapy-Resistant Disease

Choosing the Path to a Healthier Economy: Exploring the Economic Impact of Vaccine Investment

Combating Meningococcal Disease in Vulnerable Populations

Progressing Our Pipeline

Increasing Diversity in Clinical Trials

Transforming Development to Deliver 21st Century Clinical Trials

Acting (Bio)Ethically

Understanding the important differences - and associated costs - with biosimilar and generic development

Responsible Data Stewardship Advances Scientific Progress

Pursuing Breakthroughs in the Treatment of NASH

The Pfizer Sterile Injectable Business is Positioned for Future Growth